Merck enters exclusive global license deal with Scibrunch Therapeutics for SPR2015
MRK•Merck entered an exclusive global license deal with Scibrunch Therapeutics for SPR2015, an investigational oral KRAS G12D (ON) inhibitor.
1. License deal
Merck said it entered an exclusive global license deal with Scibrunch Therapeutics for SPR2015, an investigational oral KRAS G12D (ON) inhibitor.
